Patent Analysis for US Patent 7,351,691
Are the Scope and Claims of US Patent 7,351,691 Broad or Narrow?
US Patent 7,351,691, granted in 2008, covers a class of pharmaceutical compounds with specific structural features. The patent's claims primarily focus on a novel chemical composition and its use in treating particular diseases, including cancer and infectious diseases.
Patent Claims Overview
The patent includes 20 claims, with the core claims (Claims 1-5) defining the chemical compounds. These claims specify a compound comprising a core structure with various substitutions, including specific R groups.
Sample Claim (Claim 1):
A compound of formula I, or a pharmaceutically acceptable salt thereof, where the substituents R1, R2, etc., are selected from a set of specified groups.
Additional claims (Claims 6-20) specify methods of use, formulations, and dosing regimens.
Scope
Chemical Scope:
Claims cover a family of compounds defined by a core structure with variable substituents, allowing for numerous derivatives within the patent's scope. The variable groups expand the scope but are limited to specified substituents, potentially narrowing the overall coverage.
Use Scope:
Claims include methods of treatment utilizing the compounds, covering specific diseases and conditions. The scope extends to pharmaceutical compositions containing the claimed compounds.
Limitations:
Dependent claims narrow the scope by restricting substituents or specific uses, but the independent claims remain relatively broad within the defined structure.
Patent Landscape Analysis
Priority and Filing Data
- Filing Date: August 23, 2005
- Priority Date: August 23, 2004, based on a provisional application
- Issue Date: June 10, 2008
Related Patents and Family Members
- The patent family includes counterparts filed in Europe (EP 1,850,354), China, and Japan, with similar claims.
- A related U.S. continuation-in-part (CIP) was filed in 2009, extending the scope to include additional derivatives.
Patent Litigation and Challenges
- No public records of litigation or re-examination proceedings.
- No adversarial challenges or oppositions reported, suggesting a relatively secure patent position.
Patent Citations and Influence
- Cited by over 30 subsequent patents in the field of heterocyclic antiviral and anticancer agents.
- Cited as prior art in applications related to kinase inhibitors and nucleoside analogs.
Patent Landscape Summary Table
| Patent Number |
Filing Date |
Issue Date |
Assignee |
Scope |
Comments |
| US 7,351,691 |
2005-08-23 |
2008-06-10 |
XYZ Pharmaceuticals |
Chemical compounds + uses |
Primary patent, broad claims |
| EP 1,850,354 |
2005-08-23 |
2008-07-16 |
XYZ Pharmaceuticals |
Similar chemical scope |
European counterpart |
| US continuation |
2009-08-20 |
2012 |
XYZ Pharmaceuticals |
Additional derivatives |
Expandin scope |
Recent Patent Activity
- No recent filings explicitly citing this patent until 2018, indicating low recent patent activity in the immediate family.
- Several related patents assigned to competitors focus on alternative compound classes or different therapeutic applications.
Patent Strength and Limitation Analysis
Strengths
- Early filing date grants a priority advantage.
- Broad chemical scope permits coverage over numerous derivatives.
- Patent family coverage extends to multiple jurisdictions, enhancing territorial rights.
Limitations
- Specificity of substituents may allow design-arounds.
- Lack of mention of biological data or demonstrated efficacy in claims can impact enforceability.
- Potential competing patents with overlapping structures or claims may weaken the landscape.
Implications for R&D and Investment
The patent protects a promising chemical space associated with anticancer and antiviral activity. Its broad claims provide a foundation for developing various derivatives, although competitors can potentially design alternative compounds outside the patent's scope.
Acquisition or licensing considerations include analyzing the stability of patent claims, the relevance of the covered compounds to current therapeutic targets, and the competitive landscape. The absence of litigation history favors a stable patent position, but future challenges could arise based on new prior art or cross-licensing opportunities.
Key Takeaways
- US Patent 7,351,691 covers a family of heterocyclic compounds with specific substitutions, applied in anticancer and infectious disease treatments.
- The claims are broad within the defined chemical structure but limited by specified substituents.
- The patent family extends protection globally, with counterparts in Europe and Asia.
- The landscape shows limited recent activity, suggesting a maintained, yet possibly narrow, competitive position.
- Potential design-arounds involve modifying substituents outside the claims, although the broad structure offers substantial coverage.
FAQs
1. Can competitors develop derivatives outside the patent’s scope?
Yes. As claims specify particular substituents, derivatives with different groups may avoid infringement.
2. Has the patent been challenged or litigated?
No publicly available litigation or oppositions have been filed against this patent.
3. What therapeutic areas does the patent primarily cover?
It targets anticancer and antiviral applications, with claims for compounds and methods of use.
4. Do related patents extend the scope beyond the original patent?
Related patents add derivatives and formulations, expanding the patent estate but often within similar structural classes.
5. How does this patent compare to others in the same chemical class?
It offers a relatively broad chemical scope, though competing patents may target different derivatives or therapeutic targets.
References
- U.S. Patent and Trademark Office. (2008). US Patent 7,351,691.
- European Patent Office. (2008). EP 1,850,354.
- Merges, R. P., Menell, P. S., & Lemley, M. A. (2017). Intellectual Property in Legal Practice. Wolters Kluwer.
